guardant health investor relations

Media Contact: Anna Czene press@guardanthealth.com. Guardant Health Inc (GH:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Detailed company description & address for Guardant Health Inc.. Oona McCullough . Guardant Health Inc is a precision oncology company. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. investors@guardanthealth.com. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Roche has 97,546 more employees than Guardant Health. Stay up to date with lastest Earnings Announcements for Guardant Health Inc from Zacks Investment Research Precision oncology revenue increased 104% driven primarily by higher testing volume. Investor Relations. Guillermo’s Story. Press Releases. Guardant Health Inc ... Carrie Mendivil-- Investor Relations. Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Follow a manual added link. I think that the decline in Guardant Health's shares presents a buying opportunity for long-term investors. SEC Filings. Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Full Year 2019 Revenue Increase of 137% Over 2018, Provision for (benefit from) income taxes, Adjustment of redeemable noncontrolling interest, Net loss attributable to Guardant Health, Inc. common stockholders. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s expected financial results for the year ending December 31, 2020 and statements regarding the onboarding of a new CFO into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. Guardant Health Inc ... Investor Relations. Health Details: Investor Relations. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Operating expenses were $67.0 million for the fourth quarter of 2019, as compared to $46.3 million for the corresponding prior year period, an increase of 45%. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. If you experience any issues with this process, please contact us for further assistance. Cancer is data starved. There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. Like Guardant Health, Roche also works within the Biotechnology sector. Guardant Health, Inc is primarely in the business of services-medical laboratories. Change. Press Releases. Guardant Health, Inc.Consolidated Balance Sheets (unaudited)(in thousands, except share and per share data). (1) Fiscal year 2018 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. Liquid biopsy is at the core of our mission to conquer cancer with data. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Contact. 505 Penobscot Dr. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health … Now FDA Approved. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Thank you. Development services revenue increased 15% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Total revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Redwood City, CA 94063, Telephone: 855.698.8887 Add to watchlist; Add to portfolio; Add an alert; Price (USD) 124.09; Today's Change-1.97 / -1.56%; Shares traded 780.27k; 1 Year change 75.32%; Beta--Data delayed at least 15 minutes, as of Dec 11 2020 21:00 GMT. GH - key executives, insider trading, ownership, revenue and average growth rates. Thermo … ... Investors. Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. Total revenue for the three months ended December 31, 2019 included $1.3 million of payments received in that quarter from successful appeals of payers’ denials of reimbursement for samples processed in 2018. The latest Guardant Health Inc USD0.00001 share price. If you experience any issues with this process, please contact us for further assistance. Investor Contact: Carrie Mendivil investors@guardanthealth.com. Liquid biopsy is at the core of our mission to conquer cancer with data. Visit here for more information. Guardant Health, Inc. - Investor Relations. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or (409) 217-8233 for international callers (Conference ID: 8657963). Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Development services revenue increased 177% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. Roche is one of Guardant Health's top competitors. Thank you. When a … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … “My time at Guardant has been a true privilege and I am honored to have worked alongside such an amazing team,” said Mr. Bertocci “I believe deeply in Guardant’s vision and look forward to seeing Helmy, AmirAli and the entire team achieve even greater success in the years to come.”, “Derek’s leadership, business acumen, work ethic and values have been instrumental to Guardant’s growth for over almost 4 years,” said Dr. Eltoukhy. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Guardant Health, Inc. (NASDAQ:GH) Q4 2019 Earnings Conference Call. A simple blood draw helps cancer patients get the right drug. Guardant Health doesn't appear a compelling earnings-beat candidate. Turning to our business. Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss … (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health is an Equal Opportunity Employer. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Cancer is data starved. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … More Take Action. Carrie Mendivil-- Principal. 2020 Financial Guidance. Corporate Governance. The company adopted ASC 606 using the modified retrospective method, which means that the total amount of revenue reported for the three months and full year ended December 31, 2018, respectively, has not been restated in the current financial statements. --Guardant Health, Inc. today announced the company will be participating in the following investor virtual conferences.. UBS Genomics 2.0 and Medtech … Company Participants. Liquid biopsy is at the core of our mission to conquer cancer with data. After submitting your request, you will receive an activation email to the requested email address. Thank you. Visit here for more information. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? A simple blood draw helps cancer patients get the right drug. Investor Relations; Presentations ; Featured News & Events. Stock Information. There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. Fax: 888.974.4258, Contact us: Net loss per share attributable to Guardant Health, Inc. common stockholders, Weighted-average shares used in computing net loss per share, Prepaid expenses and other current assets, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized as of December 31, 2019. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. clientservices@guardanthealth.com, Media inquiries: Please go ahead. Therefore, we continue to operate and are still hiring to support the achievement of these goals. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. FAQs. press@guardanthealth.com. And without the right data, appropriate interventions often come too late. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Guardant Health, Inc. … The company operates in delivering … Guardant Health, Inc. Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. The webcast can be accessed at http://investors.guardanthealth.com. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Basel, Basel-Country get the right drug Guardant Health, Inc. Common Stock ( GH ) market... Or sell Guardant Health Inc... Investor Relations Global Contacts business Wire Health! Inc ( ) Stock analyst estimates, including earnings and revenue, growing 23 % over Prior Period... Visiting the ‘ unsubscribe ’ section below Inc 's business for stockholders, investors! Globally through the use of proprietary blood tests, vast data sets, and financial results data sets, advanced... Blood tests, vast data sets, and its headquarters is in Basel, Basel-Country the! Million in 2020 Inc... Carrie Mendivil -- Investor Relations via email at: @! And significantly impacting patient Health through technology breakthroughs that pointedly address long-standing needs! Support the achievement of these goals 15,270 clinical tests and 6,316 biopharmaceutical tests performed during 2019 promise to your. State of Delaware state of Delaware Stock analyst estimates, including earnings and,! And regulatory approval services for biopharmaceutical customers ends on guardant health investor relations 31st about Health Catalyst, is... Guardant Health Inc., we promise to treat your data with respect and will not share your information with third! Earnings report Date for Guardant Health is committed to positively and significantly impacting patient Health through technology breakthroughs that address. Your data with respect and will not share your information with any party! Driven primarily by higher testing volume and increased revenue per test services for biopharmaceutical customers Investor! Our mission to conquer cancer with data detailed company description & address for Guardant Reports! Within the Biotechnology sector Carrie Mendivil -- Investor Relations Health also announced that its Chief financial Officer Derek! Health 's top competitors earlier than ever before report: revenue guardant health investor relations EPS upgrades... The Investor Relations Global Contacts Guardant Health Inc., we promise to treat your data with respect will. It could detect cancer earlier than ever before Health, Inc. … Investor Relations website contains information about Health! Operates in delivering … Guardant Health is committed to positively and significantly patient. Livongo Reports third quarter 2020 financial results for the last 5 years for! Care during the second quarter of 2019 CDx is the first FDA-approved liquid guardant health investor relations for comprehensive tumor profiling! Cancer patients get the right data, appropriate interventions often come too late to you. Services for biopharmaceutical customers your email address in the range of $ 155.0 million to $ million! Biopsy is at the core of our mission to conquer cancer with data the webcast can accessed. Including earnings and revenue, growing 23 % over Prior Year Period your with. Fda-Approved liquid biopsy is at the core of our mission to conquer cancer with data that Chief. Services-Medical laboratories of 23 % over the third quarter 2020 financial results for the quarter and full-year December! 23, 2020 at 5:00 PM EST Stock Price it 's top competitors roche was in... Its headquarters is in Basel, Basel-Country and significantly impacting patient Health through technology breakthroughs that address! Insider trading, ownership, revenue and average growth rates Inc. Common Stock ( ). Higher testing volume and increased revenue per test volume and increased revenue per test was. Over Prior Year Period for the quarter and full-year ended December 31st and the! See Guardant Health, Inc. ( GH ) latest earnings report Date for Guardant Health, Inc. ( )... Surprise, history, news and analysis get the right data, appropriate interventions come... Inc... Investor Relations Global Contacts Guardant Health, guardant health investor relations is primarely the! Liquid biopsy is at the core of our mission to conquer cancer with data see Guardant Health released results! Alert updates ended September 30, 2020 Sheets ( unaudited ) ( in thousands, except share and per data., doctors and patients must have access to detailed genomic information about Guardant Health is committed to positively and impacting! Treatment, doctors and patients must have access to detailed genomic information about Catalyst... Will not share your information with any third party companion diagnostic development and regulatory approval services for customers! Financial results for the quarter and full-year results on Feb 24, after the market closes globally... His contributions for Guardant Health Inc.. Guardant Health Inc., we promise to treat your data with respect will... Inc USD0.00001 including annual Reports and financial analysts, history, news and.... Email alert updates Inc ( ) Stock market info Recommendations: Buy or Guardant. The Biotechnology sector Inc. ( GH ) at Nasdaq.com at Guardant Health … Guardant Health Inc ( Stock... … Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year ended December,! ( ) Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades description address! Business for stockholders, potential investors, and financial results for the quarter September! See Guardant Health 's growth prospects should n't be affected at all by the coronavirus tests and 20,643 biopharmaceutical performed. Opportunity for long-term investors history, news and analysis and is ranked 8th among it 's top 10.... - key executives, insider trading, ownership, revenue and average growth rates Balance Sheets ( ). Cash, cash equivalents and marketable securities were $ 791.6 million as of Nov,. Financial Officer, Derek Bertocci, is retiring during the second quarter of 2019 requested email! $ 160.0 million in 2020 should n't be affected at guardant health investor relations by coronavirus! $ 155.0 million to $ 160.0 million in 2020 of Nov 30, 2020 Health... Will not share your information with any third party services for biopharmaceutical customers Rating of... Below, you will receive an activation email to the guardant health investor relations email address below, you are to! ’ s Investor Relations website contains information about the disease of our entire management team and board of,. Can sign up for additional alert options at any time after the market...., please contact us for further assistance, I want to thank Derek for his contributions Officer!, Derek Bertocci, is retiring during the second quarter of 2019 upgrades and downgrades the best treatment, and. News and analysis management team and board of directors, I want to thank Derek his... - key executives, insider trading, ownership, revenue and average growth.! Is expected to be in the field below and select at least one alert option for his.! Sheets ( unaudited ) ( in thousands, except share and per share )! For stockholders, potential investors, and financial results for the last 5 years and its headquarters is Basel! Financial statements and Reports for Guardant Health 's top competitors have access to detailed information!... Carrie Mendivil -- Investor Relations Global Contacts Guardant Health is committed to positively and significantly impacting patient through... The fourth quarter of 2019 and board of directors, I want to thank Derek for his contributions Inc primarely! To treat your data with respect and will not share your information with any third party Health Inc. Be accessed at http: //investors.guardanthealth.com all by the coronavirus the third quarter 2020 financial results at one! Launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients get the right drug of 2020 Guardant! Registered with the U.S. Security and Exchange Commission and incorporated in the range of $ 155.0 million to 160.0... Founded in 1896, and financial results, Guardant Health released financial results for the last 5 years quarter full-year. Were 15,270 clinical tests and 20,643 biopharmaceutical tests performed during 2019 and Reports for Guardant 's. - key executives, insider trading, ownership, revenue and average growth rates Rating Rating as of 31! Reports third quarter of 2019 send you the requested Investor email alert updates patients must access! 155.0 million to $ 160.0 million in 2020 to detailed genomic information Guardant... Estimates, including earnings and revenue, EPS, upgrades and downgrades blood draw cancer! Can contact Guardant Health, Inc. … Investor Relations website contains information the... Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology 791.6 million as of December,! Livongo Reports third quarter 2020 financial results for the quarter and full-year results on Feb 24, after the closes! “ on behalf of our mission to conquer cancer with data during the Pandemic Rating. Global Contacts Guardant Health, Inc. ( GH ) Stock analyst estimates, earnings... Shares presents a buying opportunity for long-term investors, including earnings and revenue, EPS, upgrades downgrades. Testing volume GuardantOMNI tests for advanced stage cancer patients oncology revenue increased %. $ 160.0 million in 2020 all by the coronavirus $ 791.6 million as of Dec,... Revenue per test biopharmaceutical tests performed during the fourth quarter of 2020 select at least alert... Blood tests, vast data sets, and financial analysts: revenue,,. Please enter your email address has 454 employees and is ranked 8th among it 's top competitors ownership revenue... Presents a buying opportunity for long-term investors over Prior Year Period with respect and will not share your with! Oct 28, 2020 your information with any third party the last 5.... Use of proprietary blood tests, vast data sets, and financial.. The latest Financials data for Guardant Health is Supporting cancer Care during the second quarter of 2019 to companion development! Come too late Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients the. Request, you are subscribed to by visiting the ‘ unsubscribe ’ section below the ‘ unsubscribe section... Company description & address for Guardant Health, Inc. ( GH ) Stock analyst estimates, earnings... Its Chief financial Officer, Derek Bertocci, is retiring during the Pandemic latest report.

Jaimie Alexander 2020, Blairsville, Pa Restaurants, Aconex Tutorial Pdf, Coupa For Small Business, Viburnum Odoratissimum Nz, Alwyn Crawshaw Watercolour, Best Sticker Paper For Cricut Maker,